Vaccine hesitancy and trust in sub-Saharan Africa

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: May 13, 2024

Abstract Lack of trust is a primary reason behind the global rise in vaccine hesitancy. Existing research on trust—vaccine hesitancy nexus has almost exclusively focused COVID-19 with vast majority studies examining industrialized countries. In this study, we investigated influence different policy-relevant actors (government, science, media, pharmaceutical companies, society) for recently available vaccines related to polio and HPV which benchmark against vaccine. Leveraging unique data 5203 individuals from six countries (Ghana, Kenya, Nigeria, South Africa, Tanzania, Uganda), showed that individuals’ government society are key predictors Furthermore, demonstrated these relationships remarkably stable across vaccine, disease, country contexts.

Language: Английский

---

Say it right: measuring the impact of different communication strategies on the decision to get vaccinated

BMC Public Health, Journal Year: 2023, Volume and Issue: 23(1)

Published: June 16, 2023

Vaccine hesitancy is a concerning menace to the control of vaccine-preventable diseases. Effective health communication could promote an overall understanding importance, risks, and benefits vaccination reduce vaccine hesitancy.

Language: Английский

---

Coverage of primary and booster vaccination against COVID-19 by socioeconomic level: A nationwide cross-sectional registry study

Human Vaccines & Immunotherapeutics, Journal Year: 2023, Volume and Issue: 19(1)

Published: Jan. 2, 2023

High and equitable COVID-19 vaccination coverage is important for pandemic control prevention of health inequity. However, little known about socioeconomic correlates booster coverage. In this cross-sectional study all Norwegian adults in the national program (N = 4,190,655), we use individual-level registry data to examine by levels household income education primary (≥2 doses) (≥3 against COVID-19. We stratify analyses age groups with different recommendations report relative risk ratios (RR) 25 August 2022. 18-44 y group, individuals highest vs. lowest had 94% 79% (adjusted RR (adjRR) 1.15, 95%CI 1.14-1.15) 67% 38% (adjRR 1.55, 95% CI 1.55-1.56), while 81% 1.10, 1.10-1.10) 60% 43% 1.23, 1.22-1.24). ≥45 96% 92% 1.02, 1.02-1.02) 88% 80% 1.09, 1.09-1.09), 98% 82% 1.16, 1.16-1.16) 64% 1.33, 1.33-1.34). conclusion, document large inequalities coverage, especially vaccination, even though was free-of-charge. The results highlight need tailor information target underserved vaccination.

Language: Английский

---

Estimated global public health and economic impact of COVID-19 vaccines in the pre-omicron era using real-world empirical data

Expert Review of Vaccines, Journal Year: 2022, Volume and Issue: 22(1), P. 54 - 65

Published: Dec. 17, 2022

Background Limited data are available describing the global impact of COVID-19 vaccines. This study estimated public health and economic vaccines before emergence Omicron variant.Methods A static model covering 215 countries/territories compared direct effects vaccination to no during 13 December 2020–30 September 2021. After adjusting for underreporting cases deaths, base case analyses total deaths averted, outpatient productivity costs saved through averted outcomes. Sensitivity applied alternative assumptions.Results prevented an median (IQR) 151.7 (133.7–226.1) million 620.5 (411.1–698.1) thousand globally In sensitivity analysis applying assumption, were 2.1 million. Estimated cost savings $21.2 ($18.9–30.9) billion indirect avoided loss $135.1 ($121.1–206.4) billion, yielding a $155 infections.Conclusions Using conservative modeling approach that considered only, we have millions infections generating billions worldwide, which underscore continued importance in response COVID-19.

Language: Английский

---

Optimization methods and algorithms

Central European Journal of Operations Research, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 16, 2024

Abstract Recent results of three areas, pickup and delivery, optimal mass transportation, matching under preferences are highlighted. The topics themselves have been selected from the active research fields Hungarian Operations Research. We also provide a short summary 34th Research Conference, held in Cegléd, Hungary, August 31–September 2, 2021.

Language: Английский

---

Characteristics of humoral responses to the first coronavirus disease booster vaccine and breakthrough infection in central China: a multicentre, prospective, longitudinal cohort study

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 7, 2025

The long-term immunogenicity, adverse effects, influencing factors, and protection from booster vaccines remain unclear. Specifically, little is known regarding the humoral immunity breakthrough infections associated with COVID-19 immunization. Therefore, we evaluated reactogenicity, protective effects of first coronavirus disease vaccine 23 months before after implementation dynamic zero epidemic control measures among healthcare staff. We prospectively included 389 staff members in China negative pre-enrolment severe acute respiratory syndrome 2 test results. Neutralising serum antibodies were every two till post-booster vaccination. Breakthrough infection was recorded or confirmed by SARS-CoV-2 specific PCR testing via throat swabs participants measures. At 15-30 days vaccination, mean concentration 6.4 times above initial concentrations. Poorer antibody responses correlated male sex, longer duration, same-manufacturer vaccines, post-routine intervals >210 between primary vaccinations. Higher rates durations but not levels neutralising vaccination participants. Adverse reactions non-serious. These doses induced rapid, robust responses, maintained for only 6-7 months. Neutralizing weaker than those vaccine, predicting that may be very different other infectious pathogens.

Language: Английский

---

The effectiveness of coercive measures in motivating vaccination: Evidence from China during the COVID-19 pandemic

Global Public Health, Journal Year: 2025, Volume and Issue: 20(1)

Published: Jan. 7, 2025

Governments worldwide have implemented mandates, restrictions, and other coercive measures to secure adequate vaccine coverage, with the COVID-19 pandemic providing numerous examples. While ethics public reception of such are matters heated discussion, their effectiveness in motivating individuals get vaccinated remains incompletely understood. This study addresses that gap by analyzing data from a 2022 nationwide online survey conducted China. Respondents recruited through proportional quota sampling reflect key demographic characteristics population were asked specify vaccination status reason behind decision. Results reveal while most respondents reported getting voluntarily, 14.6% attributed government's mobilisation efforts. Moreover, members ruling Chinese Communist Party, as well favouring Western vaccines unavailable China, more likely cite for vaccination. These findings suggest can motivate substantial proportion vaccinated, especially those closely connected political system unmet preferences. Given controversy surrounding measures, this enhanced understanding could help formulating targeted policies combat infectious diseases safeguard health.

Language: Английский

---

Hesitação e Recusa da Vacina Contra a COVID-19 entre Profissionais de Saúde: Estudo Transversal num Hospital Português

Acta Médica Portuguesa, Journal Year: 2025, Volume and Issue: 38(4), P. 217 - 227

Published: April 1, 2025

Introdução: A hesitação vacinal é reconhecida pela Organização Mundial da Saúde como uma das principais ameaças à saúde global, tendo adquirido contornos singulares no contexto pandemia COVID-19. Os profissionais de são reconhecidos fontes informação mais confiáveis relativamente vacinação. sua posição perante a imunização constitui um fator determinante intenção recomendar terceiros, com potencial repercussão na taxa adesão vacina população geral. O objetivo deste estudo foi caracterizar do ponto vista sociodemográfico os hospital terciário português que recusaram vacinação contra COVID-19 e analisar motivos hesitação/recusa futuro.Métodos: Estudo observacional transversal conduzido em 2021, cuja população-alvo compreende propostos completar o esquema primário Aos vacinação, solicitado preenchimento “Questionário Não-Vacinação COVID-19”, incluía questão escolha múltipla campo resposta livre sobre pretensão futuro. Foram analisadas as variáveis ‘sexo’, ‘idade’ ‘categoria profissional’. Resultados: Entre 6648 amostra, 2,3% (n = 153) realizar completo. média idades 46 anos (DP 11), sendo proporção, cada grupo etário 1,2% ≤ 35 anos; 2,5% 36 - 45 3,1% > anos. recusa vacinal, entre total sexo, sexo feminino 2,4% masculino. Uma maior proporção ocorreu nos assistentes operacionais 53, 4,0%) técnicos 13, 3,0%). Observaram-se 16 relatados: receio reações adversas 31), investigação insuficiente vacinas 22), desconfiança eficácia 25). Apenas 28,1% 43) demonstraram Conclusão: Verificou-se elevada aceitação probabilidade semelhante ambos sexos, mas superior indivíduos operacionais. Destacaram-se pressupunham preocupações relativas segurança vacina. Estudos adicionais necessários para melhor compreensão dinâmicas subjacentes vacinal.

---

Covid-19 vaccine hesitancy among the working population in urban areas of Benue State, North-Central Nigeria

Deleted Journal, Journal Year: 2025, Volume and Issue: 22(1)

Published: April 26, 2025

Language: Английский

---

Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States

Vaccines, Journal Year: 2024, Volume and Issue: 12(1), P. 74 - 74

Published: Jan. 12, 2024

Policymakers in the United States (US) recommend coronavirus disease 2019 (COVID-19) vaccination with a monovalent 2023-2024 vaccine formulation based on Omicron XBB.1.5 variant. We estimated potential US population-level health and economic impacts of increased COVID-19 coverage that might be expected availability protein-based simpler storage requirements addition to messenger ribonucleic acid (mRNA) vaccines. A Markov model was developed estimate 1-year COVID-19-related costs, cases, hospitalizations, deaths without option. The population stratified by age risk status. Model inputs were sourced from published literature or derived publicly available data. Our five-percentage-point increase due option would prevent over 500,000 66,000 3000 deaths. These clinical outcomes translated 42,000 quality-adjusted life years (QALYs) gained an incremental cost-effectiveness ratio USD 16,141/QALY third-party payer perspective. In sensitivity analyses, most sensitive incidence severity across groups. could reduce hospitalizations is predicted cost-effective.

Language: Английский

---